Safety and Efficacy of Dalbavancin in Real Life: Retrospective Analysis of a Large Monocentric Case Series of Patients Treated for Skin/Soft Tissue and Other Difficult-to-Treat Infections.

Dalbavancin is a long-acting lipoglycopeptide, approved for treatment of skin and skin structure infections. Its PK/PD profile and safety allow for short hospital stays even in the case of difficult-to-treat infections requiring long courses of therapy, e.g.

Microplastic removal and risk assessment framework in a constructed wetland for the treatment of combined sewer overflows.

Combined sewer overflows (CSOs) release a significant amount of pollutants, including microplastics (MPs), due to the discharge of untreated water into receiving water bodies. Constructed Wetlands (CWs) offer a promising strategy for CSO treatment and have recently attracted attention as a potential solution for MP mitigation. Nevertheless, limited research on MP dynamics within CSO events and MP removal performance in full-scale CW systems poses a barrier to this frontier of application.

Disclosing the Novel Protective Mechanisms of Ocrelizumab in Multiple Sclerosis: The Role of PKC Beta and Its Down-Stream Targets.

Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for both Relapsing and Primary Progressive forms of Multiple Sclerosis (MS) treatment. OCR is postulated to act via rapid B cell depletion; however, by analogy with other anti-CD20 agents, additional effects can be envisaged, such as on Protein Kinase C (PKC). Hence, this work aims to explore novel potential mechanisms of action of OCR in peripheral blood mononuclear cells from MS patients before and after 12 months of OCR treatment.